Dextrose Injection MarketSize and Trends

The global dextrose injection market is estimated to be valued at US$ 9,512.7 million in 2020 and is expected to exhibit a CAGR of 5.7% over the forecast period (2020-2027).

Increasing incidence of diabetes and conditions associated with diabetes such as hypoglycemia is expected to drive the market growth over the forecast period

According to the World Health Organization report published in June 2020, globally, the number of people with diabetes rose from 108 million in 1980 to 422 million in 2014.

Increasing launch and approval of products is expected to drive the market growth over the forecast period

Key players operating in the market are focusing on novel product launches and approvals, in order to expand their product portfolio and increase presence in the global market.

For instance, in July 2020, Hikma Pharmaceuticals PLC (Hikma), a multinational pharmaceutical company, launched Dacarbazine for Injection with dextrose solution for the treatment of metastatic malignant melanoma. The reconstituted solution may be further diluted with 5% dextrose injection or sodium chloride injection, and administered as an intravenous infusion.

In April 2018, SteriMAx Inc., company engaged in the production, development, marketing, and distribution of essential hospital and retail pharmacy products, launched a new drug Bupivacaine Hydrochloride in 8.25% dextrose injection indicated for spinal anesthesia. It is a subarachnoid injection (spinal block).

For instance, in 2017, Clindamycin in dextrose injection (D5W) made by Water Street Healthcare Partners, a private equity firm, which focuses extensively on building market leading companies in healthcare and Celerity Pharmaceuticals LLC, which provides drug development services, was approved by the U.S. Food and Drug Administration. Clindamycin in dextrose injection (D5W) is used to treat bacterial infections such as pneumonia by inhibiting growth of bacteria in the body.

Global Dextrose Injection Market – Impact of Coronavirus (Covid-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization declared it a public health emergency. According to the World Health Organization’s report, the manifestation of coronavirus disease (COVID-19) resulted in more than 31 million infected individuals worldwide as of September 21, 2020. Furthermore, key players operating in the market are focusing on novel product launch in order to combat COVID -19. For instance, in May 2020, Hikma Pharmaceuticals PLC (Hikma, Group), a multinational pharmaceutical company, announced the launch of Propofol Injectable Emulsion, USP, 20 mL, 50 mL, and 100 mL vials with 5% dextrose injection, in the U.S. through its US affiliate, Hikma Pharmaceuticals USA Inc. Propofol injectable emulsion is provided as a ready-to-use formulation. However, should dilution be necessary, it should only be diluted with 5% Dextrose Injection, USP and it should not be diluted to a concentration less than 2 mg/mL because it is an emulsion.

Propofol Injectable Emulsion is indicated for the maintenance of sedation and anesthesia for intubated, mechanically ventilated adults in the intensive care unit. It is currently on the FDA's Drug Shortage List, following a surge in demand due to the increase in hospitalized, ventilated patients due to the COVID-19 pandemic.

Market- TrendsFurthermore, various sports initiatives taken by the Indian government for the promotion of sports among individuals suffering from disabilities. ‘Khelo India’, National Sports Development Fund Scheme for promotion of sports among individuals suffering from disabilities. According to Khelo India Program, 1,000 students are selected annually and offered a sponsorship of 5 lakhs for 8 years. Such huge participation in sports is expected to boost growth of the global dextrose injection market. Athletes use dextrose injection to treat a variety of ligament, muscle, tendon, and joint pain.